Satralizumab during early NMOSD attacks
Treatments studied
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This study looks at how well the medication satralizumab works when started early during an NMOSD attack, along with standard treatments. The aim is to see if adding this drug can help reduce the impact of the attack and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have NMOSD with a positive AQP4 antibody test, and you must be having a relapse right now.
- Your disability level due to this relapse should be not too severe to still be able to participate (EDSS of 8.5 or less).
- You must be planning to receive or already receiving standard acute relapse treatments like high-dose steroids, IVIG, or plasma exchange.
- You must be on or starting the study drug satralizumab.
- You cannot have used other biologic treatments for NMOSD in the past 6 months, and you must not have certain infections or conditions that would make satralizumab unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called modified zipper therapy for people with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4-IgG) in their blood. It aims to stop a recent attack and improve recovery.
This study looks at how well satralizumab works in people with NMOSD (a rare disorder that affects the nerves in your eyes and spine). It is for people who have had recent flare-ups and test positive for a specific antibody (AQP4). You will receive satralizumab and be followed for at least one year to see if your disease stays under control.
This trial studies inebilizumab to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are having an acute attack. It aims to reduce ongoing nerve damage and disability after a recent flare, alongside standard steroid treatment.
This study looks at treatments for people with neuromyelitis optica spectrum disorder (NMOSD) who are having a sudden attack affecting their vision or spinal cord. It aims to find out which treatments work best in everyday practice.
This early-phase study tests B001 injection to see if it can help people with neuromyelitis optica spectrum disorder (NMOSD) who have had recent relapses. It may be aimed at reducing future attacks and improving disability over time.
This trial studies satralizumab in children ages 2 to 11 with a specific type of NMOSD caused by AQP4 antibodies. It aims to see how well the medicine prevents attacks and is safe over time.
Hear when a new Neuromyelitis Optica Spectrum Disorders (NMOSD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.